Asthma is a chronic (long-term) lung condition in which airways can become inflamed and narrowed. This makes it difficult to ...

Topline results were announced from a trial evaluating albuterol/budesonide inhaler in patients with intermittent or mild persistent asthma.

Climate change could drive up demand for drugs to treat asthma, kidney disease and Alzheimer's and add to supply chain ...

In the phase 3b BATURA trial, Airsupra—a pressurized metered-dose inhaler containing albuterol and budesonide—significantly ...

Leak Rate. It is common for MDIs to lose propellant during storage. The propellant-leak rate of the test MDIs was compared with that of the controls (Figure 3). The leak rates for the Proventil ...

Airsupra (albuterol/budesonide) is a brand-name inhaler prescribed for asthma in ... t include all possible mild side effects of the drug. For more information, you can refer to the drug’s ...

AstraZeneca's Airsupra (albuterol/budesonide) met the primary endpoint in the Phase III BATURA trial, significantly reducing ...

The U.S. government plans to release a list of 101 generic drugs, available to Medicare recipients for no more than $2 each. These drugs, including penicillin and albuterol, won't require prior ...

AstraZeneca's inhaled rescue medication, Airsupra (albuterol/budesonide), has shown significant efficacy in reducing the risk ...

AstraZeneca’s BATURA phase IIIb trial of Airsupra in patients with intermittent or mild persistent asthma meets primary endpoint: Cambridge, UK Tuesday, October 8, 2024, 09:00 H ...

AstraZeneca teams up with CSPC in a $1.92 billion deal to develop YS2302018, a novel Lp(a) disruptor aimed at treating ...

Seven Proventil HFA (albuterol sulfate 6.7 g hydrofluoroalkane inhalation aerosol ... rinsed with 50 mL of mobile phase and assayed for drug content. The filter j from the impactor inlet was ...